secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001493152-21-019196
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Q2 revenue $11.2M (+105% YoY); gross margin 48% vs 29%, adj EBITDA loss narrows to $0.3M
--------------------------------------------------------------------------------

- Net revenue $11.2M (+105% vs Q2 2020); six-month revenue $21.0M (+45% YoY).
- Gross profit margin 48% (Q2 2020: 29%); loss from continuing ops improved to $3.4M from $5.5M.
- Adjusted EBITDA $(0.3)M vs $(4.2)M in prior year; cash collections hit $11.5M in Q2, DSO down 32%.
- Cash balance rose to $4.0M at July 31 from $2.8M at Dec 31, 2020; on track for >35% FY revenue growth.
- New PLA code 0245U for ThyGeNEXT at $2,919; eviCore coverage for ThyGeNEXT/ThyraMIR effective July 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315221019196/0001493152-21-019196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315221019196/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-019196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer